tiprankstipranks
Neumora Therapeutics reports Q4 EPS (71c), consensus (55c)
PremiumThe FlyNeumora Therapeutics reports Q4 EPS (71c), consensus (55c)
1M ago
JPMorgan biotech analysts to hold an analyst/industry conference call
PremiumThe Fly
JPMorgan biotech analysts to hold an analyst/industry conference call
2M ago
JPMorgan biotech analysts to hold an analyst/industry conference call
PremiumThe Fly
JPMorgan biotech analysts to hold an analyst/industry conference call
2M ago
Neumora Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
PremiumPress ReleasesNeumora Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
3M ago
Neumora Therapeutics appoints Jason Duncan as CLO
PremiumThe Fly
Neumora Therapeutics appoints Jason Duncan as CLO
4M ago
Neumora Therapeutics Appoints Jason Duncan as Chief Legal Officer
PremiumPress Releases
Neumora Therapeutics Appoints Jason Duncan as Chief Legal Officer
4M ago
Neumora Therapeutics announces NMRA-266 IND clearance, initiation Phase 1 study
PremiumThe FlyNeumora Therapeutics announces NMRA-266 IND clearance, initiation Phase 1 study
5M ago
Three new option listings and three option delistings on November 7th
PremiumThe Fly
Three new option listings and three option delistings on November 7th
5M ago
Neumora Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
PremiumPress Releases
Neumora Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100